Carbidopa

Type: Keyphrase
Name: Carbidopa
First reported Aug 27 2014 - Updated Aug 27 2014 - 1 reports

Teva Recalls ‘Super Potent’ Parkinson’s Disease Medication

Voluntary action applies to entire U.S.Teva Pharmaceutical Industries has recalled one lot of its generic Parkinson’s disease (PD) combination medication carbidopa/levodopa because it may contain too much of an active pharmaceutical ingredient.The company ... [Published PT Community - Aug 27 2014]
First reported May 16 2014 - Updated May 16 2014 - 1 reports

Deep Brain Stimulation Devices Market: Global Industry Analysis, Size,...

Transparency Market Research published a new report "Deep Brain Stimulation Devices Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019" to its report store. Browse full report: A rise in ageing population has been found ... [Published PRWeb - May 16 2014]
First reported Mar 22 2014 - Updated Mar 22 2014 - 1 reports

CARBIDOPA Tablet [Amerigen Pharmaceuticals Inc.]

First reported Mar 11 2014 - Updated Mar 11 2014 - 1 reports

CARBIDOPA Tablet [Amerigen Pharmaceuticals, Inc.]

First reported Mar 11 2014 - Updated Mar 11 2014 - 1 reports

NeuroDerm Announces Enrollment in a Second Phase 2 Study of ND0612, a Continuous Levodopa/Carbidopa Drug for the Treatment of Parkinson's Disease

REHOVOT, Israel, March 11, 2014 /PRNewswire/ --NeuroDerm, Ltd. announced today that enrollment of patients is ongoing in its second Phase II clinical trial of ND0612, a novel drug formulation for the treatment of Parkinson's disease. ND0612 is a proprietary ... [Published PR Newswire: Health - Mar 11 2014]

Quotes

Transparency Market Research published a new report "Deep Brain Stimulation Devices Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019" to its report store...

More Content

All (5) | News (2) | Reports (0) | Blogs (3) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Teva Recalls ‘Super Potent’ Parkinson’s Disease... [Published PT Community - Aug 27 2014]
Deep Brain Stimulation Devices Market: Global I... [Published PRWeb - May 16 2014]
CARBIDOPA Tablet [Amerigen Pharmaceuticals Inc.] [Published DailyMed Drug Label Updates for the last seven ... - Mar 22 2014]
CARBIDOPA Tablet [Amerigen Pharmaceuticals, Inc.] [Published DailyMed Drug Label Updates for the last seven ... - Mar 11 2014]
NeuroDerm Announces Enrollment in a Second Phas... [Published PR Newswire: Health - Mar 11 2014]
1
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
CARBIDOPA Tablet [Amerigen Pharmaceuticals Inc.] [Published DailyMed Drug Label Updates for the last seven ... - Mar 22 2014]
Updated Date: Mar 20, 2014 EST ...
CARBIDOPA Tablet [Amerigen Pharmaceuticals, Inc.] [Published DailyMed Drug Label Updates for the last seven ... - Mar 11 2014]
Updated Date: Mar 11, 2014 EST ...
NeuroDerm Announces Enrollment in a Second Phas... [Published PR Newswire: Health - Mar 11 2014]
REHOVOT, Israel, March 11, 2014 /PRNewswire/ --NeuroDerm, Ltd. announced today that enrollment of patients is ongoing in its second Phase II clinical trial of ND0612, a novel drug formulation for the treatment of Parkinson's disease. ND0612 is a proprietary ...
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.